Drugs Containing Excipient (Inactive Ingredient) STEARETH-100

Generic drugs containing STEARETH-100 excipient

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0560	STEARETH-100
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0668	STEARETH-100
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0669	STEARETH-100
Cosette Pharmaceuticals Inc	hydrocortisone valerate	0713-0720	STEARETH-100
Rebel Distributors Corp	hydrocortisone valerate	21695-730	STEARETH-100

Steareth-100 Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 3, 2026

Steareth-100 is a high-ethylene-oxide nonionic surfactant used for emulsification, solubilization, wetting, and dispersion. Its commercial outlook is tied to specialty excipient demand rather than a separately reported pharmaceutical market. Public companies do not disclose standalone Steareth-100 revenue, shipment volume, or margin data. The most supportable financial view is therefore a bottom-up assessment based on formulation adoption, regulatory qualification, supplier economics, and substitution risk.

What is Steareth-100 and how is it used in pharmaceuticals?

Steareth-100 is the polyethylene glycol ether of stearyl alcohol, generally identified as polyoxyethylene (100) stearyl ether. It is also known by trade and nomenclature variants such as PEG-100 stearyl ether and macrogol stearyl ether, although these terms should not be treated as interchangeable without confirming the exact chemical specification.

Attribute	Steareth-100 profile
Chemical class	Nonionic surfactant
Hydrophilic component	Approximately 100 ethylene oxide units
Lipophilic component	Stearyl alcohol-derived chain
Typical physical form	Wax or solid at room temperature
Primary functions	Emulsifier, solubilizer, wetting agent, dispersion aid
Main formulation relevance	Topical, oral, and selected specialty delivery systems
Key manufacturing inputs	Stearyl alcohol, ethylene oxide, catalysts, purification capacity
Principal quality risks	Residual ethylene oxide, 1,4-dioxane, peroxide formation, moisture, polydispersity
Common substitutes	Polysorbates, PEG stearates, poloxamers, macrogol glycerol hydroxystearate, alkyl polyglucosides

The high ethylene oxide content gives Steareth-100 a strong hydrophilic character and high hydrophilic-lipophilic balance. That profile supports oil-in-water emulsions and the dispersion of poorly water-soluble ingredients. The solid form can also improve handling and dosing compared with liquid surfactants.

Steareth-100 should be distinguished from polyoxyl 100 stearate. The latter is an ester formed from stearic acid and polyethylene glycol, while Steareth-100 is an ether formed from stearyl alcohol and polyethylene glycol. Their formulation behavior, impurity profiles, regulatory records, and compendial status may differ.

What pharmaceutical formulations use Steareth-100?

Steareth-100 has the strongest commercial fit in formulations where surfactant performance, emulsion stability, or wetting is more important than a large established regulatory precedent.

Topical and dermatological products

Topical creams, lotions, gels, and emulsions are the most natural application area. Steareth-100 can support:

• Oil-in-water emulsion formation
• Stability of dispersed lipophilic active ingredients
• Skin-feel and spreadability
• Wetting of poorly dispersible powders
• Compatibility with fatty alcohols and waxes

Its use may be combined with stearyl alcohol, cetyl alcohol, glyceryl stearate, carbomers, cellulose polymers, or other nonionic emulsifiers. The commercial opportunity is larger in topical products than in systemic products because topical formulations generally face fewer excipient qualification barriers than injectable and complex biologic products.

Oral solid and liquid dosage forms

Potential oral applications include wetting, solubilization, and dispersion of hydrophobic active pharmaceutical ingredients. The main adoption constraints are taste, gastrointestinal tolerance, dose level, compatibility with the active ingredient, and the availability of excipients with established oral-use records.

Steareth-100 is more likely to be used as a low-concentration functional excipient than as a high-load matrix material. Formulators may choose polysorbates, poloxamers, PEG grades, or surfactant-containing lipid systems when they need stronger regulatory precedent or more extensive development data.

Parenteral and biologic formulations

Parenteral use has a higher qualification threshold. Developers typically prioritize excipients with substantial injectable-use history, strong compendial support, and extensive data on degradation products and subvisible particles. Polysorbate 20, polysorbate 80, poloxamer 188, and selected PEG derivatives have a stronger established position in many biologic formulations.

Steareth-100 may therefore face a significant substitution barrier in injectable products unless a sponsor has generated product-specific safety, compatibility, extractables, leachables, and stability data.

What drives demand for Steareth-100?

Demand is driven by five commercial factors.

Poorly soluble drug development

A large share of new small-molecule drug candidates has limited aqueous solubility. Surfactants remain important tools for wetting, dissolution enhancement, emulsification, and lipid-based delivery. This supports a long-term demand base for nonionic excipients, including Steareth-100.

The demand effect is stronger when a surfactant can be processed into a stable formulation without extensive equipment modification. The effect is weaker when the active requires a high surfactant concentration or when the formulation must meet stringent parenteral impurity limits.

Growth in topical and consumer-health products

Dermatology, wound care, cosmetic-drug combinations, and over-the-counter products generate recurring demand for emulsifiers. Steareth-100 benefits when formulators want a solid, high-HLB surfactant that works with fatty alcohols and waxes.

This segment is commercially attractive because repeat production volumes can be high, but pricing is usually more competitive than in specialized injectable excipients.

Demand for multifunctional excipients

Drug developers prefer excipients that perform more than one function. Steareth-100 can combine emulsification, wetting, and dispersion roles. This can reduce the number of formulation components, simplify processing, and improve product appearance.

Regional manufacturing growth

Asia-Pacific manufacturing expansion supports demand for functional excipients used in generic drugs, topical medicines, contract manufacturing, and personal-care products. Local qualification of equivalent grades can increase price competition while expanding overall volume.

Supply-chain localization

Pharmaceutical manufacturers increasingly qualify alternative sources for critical raw materials. Steareth-100 can benefit from dual sourcing because it is manufactured from commodity-linked inputs and is not protected by drug patents. Qualification remains the principal barrier, particularly when a manufacturer has validated a specific grade, particle form, or impurity profile.

How large is the Steareth-100 market?

No authoritative public market dataset isolates Steareth-100 from the broader categories of nonionic surfactants, pharmaceutical emulsifiers, or specialty excipients. Market reports that group Steareth-100 with surfactants or cosmetic emulsifiers should not be interpreted as product-specific revenue estimates.

The market is best characterized as niche and fragmented:

Market characteristic	Assessment
Product-specific public revenue	Not separately disclosed
Demand structure	Formulation-driven and qualification-driven
Volume profile	Smaller than major polysorbates and PEG excipients
Pricing	Higher than commodity surfactants when pharmaceutical documentation is included
Margin profile	Supported by qualification, documentation, and consistency rather than chemistry alone
Substitution risk	Moderate to high
Main growth areas	Topicals, emulsions, poorly soluble compounds, specialty delivery systems
Main limits	Limited regulatory precedent, competition from established excipients, batch qualification

The value of a pharmaceutical-grade Steareth-100 product is determined by more than the chemical material. Documentation, GMP controls, traceability, impurity testing, change-control procedures, and regulatory support can materially increase the selling price relative to industrial or cosmetic grades.

Which companies supply or compete with Steareth-100?

Steareth-100 is supplied through specialty surfactant and excipient channels rather than through a single dominant pharmaceutical franchise. Relevant supplier groups include:

• Specialty excipient manufacturers
• Pharmaceutical raw-material distributors
• Contract manufacturers with proprietary emulsifier systems
• Cosmetic-ingredient suppliers that also offer pharmaceutical documentation
• Regional producers of ethoxylated fatty alcohols

Croda and other specialty-ingredient companies have marketed ethoxylated fatty alcohol products under Brij and related product families. Exact grade identity, regulatory status, and intended use must be verified by product-specific technical and quality documents. A commercial product with a similar trade name may not have the same molecular-weight distribution or pharmaceutical qualification as another supplier's Steareth-100 grade.

The competitive set includes:

Alternative	Competitive advantage	Limitation versus Steareth-100
Polysorbate 20	Extensive pharmaceutical and biologic precedent	Oxidative degradation and peroxide concerns
Polysorbate 80	Broad formulation use and established regulatory history	Oxidation, hydrolysis, and lot variability
Poloxamer 188	Strong parenteral and biologic formulation history	Different rheology and surfactant behavior
PEG stearates	Familiar fatty ester chemistry	Different hydrolysis and emulsification profile
Macrogol glycerol hydroxystearate	Strong solubilization performance	More complex composition and qualification profile
Alkyl polyglucosides	Renewable feedstock positioning	Less established pharmaceutical use in some regions

What is the regulatory status of Steareth-100?

Steareth-100 does not have the same universal regulatory position as the most widely used pharmaceutical excipients. Regulatory status depends on the exact chemical identity, grade, route, concentration, dosage form, and jurisdiction.

United States

The FDA Inactive Ingredient Database is the primary public reference for excipients used in approved drug products. An entry must be checked under the precise substance name and route. Similar names, such as polyoxyl stearates, do not establish that Steareth-100 itself has the same regulatory precedent. FDA approval of a finished product also does not create broad approval of the excipient for every route or concentration.[1]

European Union

European developers assess excipients under the applicable European Pharmacopoeia framework, European Medicines Agency expectations, national authority practice, and product-specific quality documentation. A pharmaceutical-grade material may be usable without having a dedicated monograph, but the sponsor must still justify identity, specifications, manufacturing controls, safety, and suitability for the proposed use.

Quality and impurity controls

Ethoxylated materials require controls for:

• Residual ethylene oxide
• 1,4-dioxane
• Free ethylene oxide-derived oligomers
• Peroxides and oxidative degradation products
• Residual solvents
• Heavy metals and elemental impurities
• Microbial quality where applicable
• Molecular-weight distribution and degree of ethoxylation

ICH Q3C and Q3D are relevant where residual solvents and elemental impurities apply to the finished product and excipient control strategy.[2,3] USP General Chapter <1059> provides a framework for excipient functionality and material attributes, but it does not by itself establish a Steareth-100 monograph or approval pathway.[4]

What manufacturing barriers affect Steareth-100?

The chemistry is commercially accessible, but pharmaceutical production is more demanding than industrial ethoxylation.

Feedstock and process economics

The principal cost drivers are:

1. Stearyl alcohol pricing
2. Ethylene oxide pricing and availability
3. Energy consumption
4. Reactor utilization
5. Purification and stripping
6. Analytical testing
7. Packaging and controlled storage
8. Documentation and quality-system overhead

Ethylene oxide supply is concentrated and subject to safety, transport, and regulatory controls. A disruption can affect multiple ethoxylated surfactants simultaneously. Stearyl alcohol prices are linked to fatty alcohol markets, which are influenced by palm, palm-kernel, oleochemical, and petrochemical supply chains.

Batch consistency

A nominal "100 EO" material is not a single molecular species. Its performance depends on the distribution of ethoxylate chain lengths, unreacted fatty alcohol, free polyethylene glycol, moisture, and crystallinity. Pharmaceutical buyers may require tighter control than cosmetic buyers, increasing testing and manufacturing cost.

Sustainability and regulatory scrutiny

Ethoxylated surfactants face scrutiny over petrochemical inputs, palm-derived feedstocks, wastewater behavior, and residual 1,4-dioxane. Suppliers with traceable feedstocks, lower-impurity processes, and credible environmental documentation may achieve better retention and pricing.

What is the financial trajectory for Steareth-100?

The likely financial trajectory is modest volume growth with pricing determined by grade and qualification rather than by broad market expansion.

Scenario	Commercial trajectory	Main assumptions
Base case	Low- to mid-single-digit annual value growth	Stable topical demand, selective oral adoption, continued substitution pressure
Upside case	Mid- to high-single-digit value growth	New delivery-system adoption, stronger pharmaceutical-grade positioning, supply diversification
Downside case	Flat or declining value	Replacement by polysorbates, poloxamers, PEG esters, or lower-cost local grades

Standalone revenue cannot be calculated from public filings because suppliers generally report ethoxylated surfactants within broader life-science, consumer-care, or specialty-chemical segments. The more useful financial indicators are:

• Number of qualified pharmaceutical customers
• Repeat order rate
• Share of revenue from pharmaceutical grade versus cosmetic grade
• Average selling price per kilogram
• Gross margin after analytical and documentation costs
• Customer concentration
• Capacity utilization
• Approval-related switching costs
• Raw-material pass-through mechanisms

A supplier with a validated pharmaceutical grade can earn better margins than a commodity producer even when its chemical conversion cost is similar. The margin premium is vulnerable when customers qualify two or more equivalent sources. Qualification creates retention, but it does not create durable exclusivity.

What generic launch risks and patent issues apply?

Steareth-100 is an excipient, not an active pharmaceutical ingredient. It generally has no Orange Book listing, no Paragraph IV litigation profile, and no drug patent exclusivity timeline of its own. Generic launch risk arises indirectly through the finished drug's formulation and manufacturing patents.

A generic manufacturer may face:

• Formulation patents covering a specific surfactant combination
• Method-of-use patents covering treatment with the finished product
• Process patents covering emulsification, granulation, or particle-size control
• Device patents for delivery systems
• Trade-secret barriers involving mixing order, temperature, or processing parameters

Using Steareth-100 does not by itself infringe a patent. The relevant analysis is whether the selected grade, concentration, process, and finished dosage form fall within claims covering the branded product.

How strong is the commercial position of Steareth-100?

Steareth-100 has moderate technical utility but a weaker defensibility profile than proprietary delivery technologies or highly regulated injectable excipients.

Its strengths are:

• Broad emulsification and wetting functionality
• Compatibility with many oil-in-water systems
• Solid handling characteristics
• Potential use across topical and oral formats
• Availability from multiple specialty-chemical channels

Its weaknesses are:

• Limited product-specific public market data
• Strong substitution by established nonionic surfactants
• Regulatory variability by route and jurisdiction
• Sensitivity to impurity and molecular-distribution specifications
• Limited ability to secure patent-based pricing power

The commercial advantage belongs to suppliers that combine consistent chemistry with pharmaceutical documentation, low impurity levels, validated change control, and reliable regional supply.

Key Takeaways

• Steareth-100 is a high-EO nonionic surfactant used mainly for emulsification, wetting, solubilization, and dispersion.
• Topical formulations are the clearest commercial growth area.
• Oral and parenteral use is possible but faces greater qualification and regulatory barriers.
• No public source separately reports Steareth-100 revenue, market share, or supplier margin.
• Financial performance depends on pharmaceutical-grade qualification, documentation, and supply reliability.
• Polysorbates, poloxamers, PEG stearates, and macrogol glycerol hydroxystearate are the main substitutes.
• Raw-material costs are exposed to ethylene oxide, stearyl alcohol, energy, and specialty-chemical logistics.
• Steareth-100 has no standalone Orange Book, Paragraph IV, or drug-exclusivity profile.
• Finished-product patents may still affect formulations that use Steareth-100.
• The base-case outlook is low- to mid-single-digit value growth, with upside from specialty delivery systems and downside from substitution.

FAQs

Is Steareth-100 the same as polysorbate 80?

No. Steareth-100 is a polyethylene oxide ether of stearyl alcohol. Polysorbate 80 is a sorbitan ester mixture containing oleate chains and polyethylene oxide segments. They have different structures, impurity profiles, regulatory histories, and formulation behavior.

Can Steareth-100 be used in injectable drugs?

Potentially, but use depends on the exact grade, route, concentration, impurity profile, toxicology, and product-specific regulatory justification. Established injectable surfactants generally have a lower qualification burden.

Does Steareth-100 have a USP-NF monograph?

A dedicated monograph should not be presumed from the chemical name or a supplier trade name. The applicable USP-NF status must be confirmed against the current compendium and the exact material specification.

Is Steareth-100 suitable for biologic formulations?

It may be technically evaluated for selected biologic formulations, but polysorbates and poloxamers have substantially stronger precedent in many biologic products. Compatibility, aggregation, oxidation, particles, and container interaction require product-specific testing.

Can pharmaceutical manufacturers switch Steareth-100 suppliers without regulatory impact?

A supplier change can require comparability, quality-risk assessment, stability data, and regulatory reporting. The extent depends on the dosage form, regulatory filing, material specifications, and whether the change alters critical quality attributes.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. International Council for Harmonisation. (2021). ICH Q3C(R8): Impurities: Guideline for residual solvents. https://www.ich.org/page/quality-guidelines
3. International Council for Harmonisation. (2019). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org/page/quality-guidelines
4. United States Pharmacopeia. (2024). General Chapter <1059> Excipient performance. In United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
5. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.
6. National Center for Biotechnology Information. (n.d.). PubChem compound summary: Polyoxyethylene stearyl ether. PubChem. https://pubchem.ncbi.nlm.nih.gov/